Efficacy and safety of once-daily minoxidil foam 5% versus twice-daily minoxidil solution 2% in female pattern hair loss: A phase III, randomized, investigator-blinded study

Ulrike Blume-Peytavi, Jerry Shapiro, Andrew G. Messenger, Maria K. Hordinsky, Paul Zhang, Carlos Quiza, Uday Doshi, Elise A. Olsen

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Background: A once-daily minoxidil topical foam (MTF) has been developed to treat female pattern hair loss. Objective: Determine noninferiority of once-daily 5% MTF versus twice-daily 2% minoxidil topical solution (MTS) based on the change from baseline in target area hair count (TAHC) at 24 weeks. Methods: In a randomized, phase III trial, women with female pattern hair loss received once-daily 5% MTF (n=161) or twice-daily 2% MTS (n=161) for 52 weeks. Primary endpoint was change from baseline in TAHC at 24 weeks. Secondary endpoint was change from baseline in TAHC at 12 weeks. Exploratory endpoints included change in total unit area density and change in overall scalp coverage. Results: Once-daily 5% MTF increased TAHC from baseline (adjusted mean ± standard error) by 23.9 ± 2.1 hairs/cm2 at week 24. Twice-daily 2% MTS increased TAHC 24.2 ± 2.1 hairs/cm2 at week 24. The treatment difference was -0.3 hairs/cm2 (95% CI = -6.0, 5.4). Since the lower bound of the 95% CI was less than -5.0, the prespecified noninferiority goal was not met. Both treatments were well tolerated. Conclusions: Once-daily 5% MTF and twice-daily 2% MTS induced hair regrowth in female pattern hair loss, but prespecified noninferiority criteria were not met.

Original languageEnglish (US)
Pages (from-to)883-889
Number of pages7
JournalJournal of Drugs in Dermatology
Volume15
Issue number7
StatePublished - Jul 2016

Bibliographical note

Funding Information:
This study was sponsored by Johnson &Johnson Consumer Inc. Dr. Blume-Peytavi is a consultant for Johnson &Johnson Consumer Inc., Galderma, and Pierre Fabre. Dr. Shapiro is a consultant for Johnson &Johnson Consumer Inc., Merck, Allergan, Applied Biology, and a co-founder and shareholder of Replicel Life Sciences Inc. Dr. Hordinsky is a consultant for Johnson &Johnson Consumer Inc., Novartis, and Allergan, and receives grant support from Intrepid and the National Alopecia Areata Foundation. Drs. Zhang, Quiza, and Doshi are employees of Johnson &Johnson Consumer Inc., sponsor of the trial. Dr. Olsen is a consultant for GSK, Allergan, and Canfield Scientific, receives research support from North American Hair Research Society and Duke University, and receives other support from Allergan. Dr. Messenger has no conflicts of interest to declare.

Publisher Copyright:
Copyright © 2016 Journal of Drugs in Dermatology. All Rights Reserved.

Fingerprint

Dive into the research topics of 'Efficacy and safety of once-daily minoxidil foam 5% versus twice-daily minoxidil solution 2% in female pattern hair loss: A phase III, randomized, investigator-blinded study'. Together they form a unique fingerprint.

Cite this